期刊
EXPERIMENTAL NEUROLOGY
卷 233, 期 1, 页码 472-480出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2011.11.021
关键词
Amyotrophic lateral sclerosis; Prognostic factors; Neurotrophic factors; Mesenchymal stromal cells
资金
- Ministry for Health, Welfare & Family Affairs, Republic of Korea [A101712]
Amyotrophic lateral sclerosis (ALS) is caused by motor neuron death. The relationship between the prognosis of ALS patients and the function of their bone marrow mesenchymal stromal cells (BM-MSCs) is unclear. We designed this study to assess the correlation between the progression rate of the ALS Functional Rating Scale-revised version (Delta FS), which is reported to predict prognosis, and the pluripotency and trophic factor secreting capacity of ALS patients' BM-MSCs. We evaluated Delta FS in 23 ALS patients and isolated BM-MSCs from those patients and five healthy people. Levels of Nanog, Oct-4, and Nestin mRNA were examined to evaluate pluripotency, and levels of BDNF, ECGF1, bFGF-2, HGF, IGF-1, PGF, TGF-1 beta, SDF-1 alpha, GDNF, VEGF, and ANG mRNA were examined to assess trophic factor secreting capacity. In addition, we measured the protein levels of Nanog, Oct-4, Nestin, SDF-1 alpha, ANG, bFGF-2, VEGF, IGF-1, GDNF, and BDNF. mRNA levels of Nanog, Oct-4, ECGF1, bFGF-2, HGF, IGF-1, PGF, TGF-1 beta, SDF-1 alpha, GDNF. VEGF, and ANG were negatively correlations with Delta FS. However, those of Nestin and BDNF were not significantly correlated with Delta FS. Similarly, Nanog, Oct-4, SDF-1 alpha, ANG, bFGF-2, VEGF, IGF-1, and GDNF protein levels had a significant negative correlation with Delta FS. Results indicate that the pluripotency and trophic factor secreting capacity of the BM-MSCs of ALS patients are reduced in proportion to a poorer prognosis. We therefore suggest that healthy allogeneic BM-MSCs might be a better option for cell therapy in ALS patients. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据